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ABSTRACT
Neovascular retinopathies are leading causes of irreversible blindness. Although 
vascular endothelial growth factor (VEGF) inhibitors have been established as 
the mainstay of current treatment, clinical management of these diseases is still 
limited. As retinal impairment involves abnormal neovascularization and neuronal 
degeneration, we evaluated here the involvement of galectin-1 in vascular and 
non-vascular alterations associated with retinopathies, using the oxygen-induced 
retinopathy (OIR) model. Postnatal day 17 OIR mouse retinas showed the highest 
neovascular profile and exhibited neuro-glial injury as well as retinal functional loss, 
which persisted until P26 OIR. Concomitant to VEGF up-regulation, galectin-1 was 
highly expressed in P17 OIR retinas and it was mainly localized in neovascular tufts. In 
addition, OIR induced remodelling of cell surface glycophenotype leading to exposure 
of galectin-1-specific glycan epitopes. Whereas VEGF returned to baseline levels at 
P26, increased galectin-1 expression persisted until this time period. Remarkably, 
although anti-VEGF treatment in P17 OIR improved retinal vascularization, neither 
galectin-1 expression nor non-vascular and functional alterations were attenuated. 
However, this functional defect was partially prevented in galectin-1-deficient 
(Lgals1-/-) OIR mice, suggesting the importance of targeting both VEGF and galectin-1 
as non-redundant independent pathways. Supporting the clinical relevance of these 
findings, we found increased levels of galectin-1 in aqueous humor from patients 
with proliferative diabetic retinopathy and neovascular glaucoma. Thus, using an OIR 
model and human samples, we identified a role for galectin-1 accompanying vascular 
and non-vascular retinal alterations in neovascular retinopathies.
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INTRODUCTION
Proliferative neovascular retinopathies are major 
leading causes of blindness in industrialized countries [1]. 
Vision loss in retinopathy of prematurity and proliferative 
diabetic retinopathy are caused by several growth factors 
[2, 3], including vascular endothelial growth factor-A 
(VEGF-A), the most potent cytokine that mediates 
ischemia-induced retinal neovascularization (NV) in 
ocular pathologies [4, 5]. VEGF-A exerts its effects 
via activation of various signaling events, including 
tyrosine phosphorylation of its receptors VEGFR1 (Flt-
1), VEGFR2 (KDR/Flk-1), and VEGFR3 (Flt-4) and their 
downstream effectors on endothelial cells (ECs) [6].
Accumulating evidences, stemming from 
experimental models and clinical studies have provided 
insights into the mechanisms of vascular injury leading 
to pathological vitreoretinal NV, leading to discovery 
and implementation of ocular anti-VEGF therapies [7]. 
Bevacizumab (Avastin; Genentech, San Francisco, CA), 
ranibizumab (Lucentis; Genentech, San Francisco, CA), 
and aflibercept (Eylea; Regeneron Pharmaceuticals, 
Tarrytown, NY) are the most widely used anti-VEGF 
drugs administered by intravitreal injection in ocular 
pathologies. However, the clinical benefit conferred by 
these therapies is variable and the results have not always 
been successful in preserving retinal function [2].
In addition to the vascular component of neovascular 
retinopathies, several studies have shown that local 
neurons and glial cells are also affected in the ischemic 
retina and their dysfunction may exacerbate the aberrant 
angiogenic phenotype and contribute to progression of 
the disease [8-10]. In fact, Müller glial cells contribute 
to the development of pathological NV [11-14] and 
neurodegeneration plays a significant role in microvascular 
impairment [15], indicating that dual targeting of both 
vascular and neural compartments may represent an 
effective strategy for treating this multifactorial disease. 
Thus, a next generation of pharmacological agents for 
neovascular retinopathies should prevent or improve both 
pathological NV as well as neuron and glial alterations. 
In this regard, the mouse model of oxygen-induced 
retinopathy (OIR) has been instrumental for understanding 
the mechanisms underlying retinal pathogenesis as well 
for developing groundbreaking therapeutics offering an 
opportunity to examine the role of hypoxia and hypoxia-
regulated genes in the pathogenesis of retinal NV, 
neuroinflammation, oxidative stress and neurovascular 
cross-talk [16].
Galectin-1 (Gal1), a member of a highly conserved 
family of animal lectins, has been implicated in 
angiogenesis-related disorders including cancer and 
endometriosis through hypoxia-inducible factor 1 (HIF-
1α)- and VEGF-independent pathways [17-22]. Gal1 
recognizes poly-N-acetyllactosamine (LacNAc) structures 
in N- and O- glycans present on a selected repertoire 
of glycosylated receptors [23] and promotes tumor 
progression through mechanisms involving promotion of 
tumor vascularization, immunosuppression and metastasis 
[24-27]. Interestingly, Gal1 is upregulated by hypoxia 
[17, 28] and controls ECs signaling [17] and VEGFR2 
trafficking [29]. Moreover, we found that glycosylation-
dependent programs mediated by Gal1 association to 
VEGFR2 promote VEGF-like signaling and preserve 
angiogenesis in anti-VEGF refractory tumors [30]. 
In this study we evaluated the contribution of Gal1 
to functional impairment during the pathogenesis of 
experimental neovascular retinopathies and its regulated 
expression during the development of vascular and non-
vascular alterations using the OIR model in mice treated 
or not with anti-VEGF mAb. Moreover, we validated the 
clinical relevance of these observations in aqueous humor 
of diabetic patients with neovascular retinopathies.
RESULTS
Increased expression of Gal1 during retinal 
impairment in the OIR model
In order to explore vascular and non-vascular 
alterations associated to neovascular retinopathies and 
the consequent functional retinal loss, we first analyzed 
NV, neurodegeneration and electroretinogram responses 
in the OIR mouse model. Figure 1A summarizes the 
most important functional hallmarks featuring different 
individual time periods in this animal model [31]. At 
P12 OIR, a pronounced vaso-obliteration (VO) effect 
generated by hyperoxia was observed. Moreover, during 
the relative hypoxic period, animals developed extensive 
retinal NV (peak is reached at P17) and from P17 onward 
NV declined, until P25 where almost no VO or NV 
remained visible as described [32].
GSA-IB4 lectin-labeled blood vessels in flat-mount 
retinas showed, at P17 OIR, a central zone of VO in 
addition to the characteristic vitreoretinal neovascular 
tufts, which were not observed in P17 room air controls 
(RA) (Figure 1B). Moreover, TUNEL-positive nuclei 
were detected in the ganglion cell layer (GCL), within 
the inner nuclear layer (INL; mainly neurons such as 
bipolar and amacrine cells), as well as in outer nuclear 
layer (ONL; photoreceptors) in OIR retinas (Figure 1C). 
Quantitative analysis showed that TUNEL-positive cells 
were significantly higher in P12 and P17 OIR compared to 
control mice (RA), with a significant increase at day P26 
OIR (Figure 1D). Besides, Western blot analysis of retinas 
from RA and OIR mice revealed decreased levels of total 
caspase-3 protein in P26 OIR (Figure 1E), suggesting 
an increased expression of its cleaved form [33]. In 
addition, expression of glial fibrillary acidic protein 
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Figure 1: Neovascularization, neurodegeneration, glial activation and functional loss in OIR mouse retinas. A. Scheme 
representing the OIR mouse model with hallmark time points during experimental disease development. Neonatal mice and their nursing 
mother are kept in room air from birth to P7 and normal vascular development ensues. At P7, they are exposed to 75% oxygen, which 
inhibits retinal vessel growth and causes significant VO. Mice are returned to room air at P12; the avascular retina becomes hypoxic, eliciting 
both normal vessel regrowth and pathological neovascular response. NV reaches its maximum at P17. Shortly thereafter, it spontaneously 
regresses and the vascular alterations resolve by P25. This scheme is adapted from Connor KM et al. Nat Protoc. 2009;4:1565-1573. B. 
Representative images of whole mount retinas at P17 showing GSA-IB4 vascular staining in RA and OIR mice. Areas with VO and NV 
are indicated. Scale bar: 100 µm. C. Representative TUNEL cryosections labeling of RA and OIR mice, at P17 and P26. Scale bar: 50 µm. 
Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer 
nuclear layer. Arrows are indicating TUNEL-positive nuclei. D. Quantification of the TUNEL-positive cells between both groups at P17 
and P26 are shown. E. and F. Representative Western blot of total caspase-3, GFAP and GS from neural retinal extracts of RA and OIR mice 
at P12, P17 and P26. β-actin is shown as a loading control. G. Levels of GFAP and GS were quantified by densitometry and normalized 
by β-actin. Graph shows results from four independent experiments. H. Amplitudes and latencies of a- and b-waves from scotopic ERG 
were recorded at P17 and P26 in RA and OIR mice. Data show the average of responses over both eyes, in five mice per condition. Data 
are presented as mean ± SEM. ns, non-significant, *p < 0.05, **p < 0.01, *** p < 0.001.
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(GFAP) substantially increased in P17 and even more in 
P26 OIR respect to RA mouse retinas (Figures 1F and G), 
in accordance with activation of Müller glial cells in the 
mouse model. Moreover, we observed lower expression of 
glutamine synthase (GS) in both P17 and P26 OIR respect 
to RA mouse retinas suggesting impairment in glutamate 
detoxification (Figures 1F and 1G). 
Next, we analyzed the functional status of retinas 
by scotopic electroretinography (ERG). Amplitude and 
latency of electroretinogram a- and b- waves at P17 and 
P26 of RA and OIR mice were registered. The b-wave 
amplitude was significantly reduced in OIR compared to 
RA mice. Also, a- and b- wave latencies were significantly 
increased in P26 OIR, and a tendency toward larger 
latencies was observed in P17 OIR mice respect to RA 
(Figure 1H), indicating that retinal dysfunction was 
progressive. These results show that, although retinal NV 
and VO were completely resolved in this mouse model, 
neuronal damage, glial activation and functional loss 
persisted until P26 OIR.
Seeking for VEGF-independent pathways that could 
modulate neovascular retinopathies outcome, we explored 
the relevance of Gal1 in the pathogenesis of this retinal 
disease using the OIR mouse model. We measured Gal1 
and VEGF expression by Western blot in RA vs. OIR mice 
at critical time points (Figure 2A). Interestingly, Gal1 
expression increased during retinal development in RA, 
being statistically higher in P26, but not in P17 respect to 
P12 RA (data not shown). Quantitative analysis revealed 
that Gal1 protein levels were significantly higher in retinas 
of P17 and P26 OIR compared to RA mice; while, as 
expected, VEGF protein levels peaked at P17 returning 
to baseline levels at P26 (Figure 2B). In addition, Gal1 
mRNA levels significantly increased in the neurosensory 
retina at P17 and P26, suggesting that the OIR condition 
induces Gal1 expression in the retina (Figure 2C). 
Then, we analyzed Gal1 localization in retinas of 
both normal and pathological groups (RA and OIR) 
by immunofluorescence assays. Confocal microscopy 
analysis revealed that Gal1 was localized within the inner 
layers of the retina, mainly at the inner limitant membrane 
(ILM) and GCL under retinal development; however, 
in the peak of the NV of the OIR mouse model (P17), 
expression of this lectin was most prominent in the most 
highly vascularized area (Figure 2D, upper panel). Higher 
Gal1 expression, occurred at the same time as the neural 
retina modified its structure in response to hypoxia and 
the Müller glial cells initiated an activation program as 
confirmed by GFAP positive staining (Figure 2D, second 
panel). To determine the cellular sources contributing to 
Gal1 expression, immunofluorescence was performed 
using a combination of two different anti-Gal1 antibodies 
(mouse monoclonal and rabbit polyclonal antibodies) 
along with anti-GFAP (rabbit polyclonal), anti-GS 
(rabbit polyclonal) or anti-CD31 (PCAM-1) (mouse 
monoclonal) antibodies and colocalization studies were 
carried out. Increased colocalization of Gal1 and GFAP 
was observed by confocal microscopy at P17 and P26 RA 
mice retinas, suggesting that Gal1 is present in astrocytes 
and in the endfeet of activated Müller glial cells in OIR, 
mainly at P17 (Figure 2D, second panel). GS and Gal1 
colocalization in P17 OIR mouse retinas strengthened this 
observation (Figure 2D, third panel). Then, we examined 
whether CD31+ cells were also positive for Gal1 given 
that CD31 makes up a large portion of endothelial cell 
intercellular junctions. Results demonstrated that Gal1 did 
not colocalize with CD31 at any of the times evaluated; 
however, a relationship between signals was detected 
(Figure 2D, bottom panel). At higher magnification, Gal1 
was detected surrounding CD31+ cells in P17 RA mouse 
retinas (normal vessels); nevertheless, during the peak of 
the NV (P17 OIR), Gal1 was also found in neovascular 
tufts within CD31+ cells (Figure 2E). Thus, up-regulation 
of Gal1 during OIR and its localization in areas with high 
NV as well as inside neovascular tufts, suggest a role for 
this endogenous lectin in the pathogenesis of experimental 
neovascular retinopathies.
Differential glycosylation profile of mouse retinas 
in RA and OIR
As Gal1 modulates cellular programs by recognizing 
poly-LacNAc structures in N- and O- glycans present on 
a selected repertoire of glycosylated receptors [24], we 
examined the ‘glycosylation signature’ of mouse retinas 
during development (RA) and following exposure to 
hypoxic stimuli (OIR), using a panel of biotinylated lectins 
that recognize specific glycan structures particularly 
those that are relevant for Gal1 binding [30]. Staining 
by: a) Lycopersicon esculentum lectin (LEL) which 
recognizes poly-LacNAc structures (Figure 3A, upper 
panel); b) L-phytohemagglutinin (L-PHA) which binds 
to β1-6-N-acetylglucosamine (β1-6GlcNAc)-branched 
complex N-glycans, which are the preferred intermediates 
for LacNAc extension (Figure 3B, upper panel); and c) 
Sambucus nigra agglutinin (SNA) (Figure 3C, upper 
panel) which recognizes α,6-linked sialic acid, revealed 
considerable changes in the glycosylation pattern of 
mouse retina during development and when exposed to 
hypoxic conditions. Notably, colocalization of LEL with 
Gal1 was almost complete in retinas at P17 in both RA 
and OIR (Figure 3A, bottom panel). However, in OIR, 
L-PHA reactivity was much more intense than control 
conditions and the colocalization with Gal1 was greater in 
areas with NV at P17 in OIR respect to RA retinas (Figure 
3B, bottom panel), suggesting that Gal1 may preferentially 
associate with elongated LacNAc structures present in 
complex branched N-glycans. Finally, SNA reactivity 
predominated in GCL and INL, was markedly decreased in 
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Figure 2: Gal1 expression and localization in RA and OIR mouse retinas. A. Representative Western blot of Gal1 and VEGF 
from neural retina extracts of RA and OIR mice at P12, P17 and P26. β-actin is shown as a loading control. B. Levels of Gal1 and VEGF 
were quantified by densitometry and normalized by β-actin. Results of at least four independent experiments are shown. C. Gal1 mRNA 
was quantified by qRT-PCR in neurosensory retinas of P17 and P26 OIR mice or RA (control) conditions. Results were normalized to 
β-actin and expressed according to the 2-ΔΔCt method using as calibrator the mRNA level obtained from P17 RA mouse retinas. Data are 
presented as mean ± SEM. ns, non-significant, *p < 0.05, **p < 0.01, *** p < 0.001. D. Representative immunofluorescence analysis of 
Gal1 (green) in cryosections of RA and OIR mouse retinas at P12, P17 and P26 (first panel). Double labeling using a mouse monoclonal 
antibody for Gal1 (green) and an astrocyte and activated MGC marker, anti-GFAP (red) (second panel), or a MGC-specific marker, anti-
GS (red) (third panel) and a rabbit polyclonal anti-Gal1 (red) in combination with an endothelial cell marker, anti-CD31 (green) (fourth 
panel). Cell nuclei were counterstained with Hoechst 33258 (blue). Scale bar: 25 µm. E. High magnification confocal micrograph of 
the representative P17 RA and OIR retinas showing a typical vessel (left panel) and a neovascular tuft (right panel). Images were taken 
with silicon 60X objective in the best confocal resolution condition and spatial deconvolution was done with the Huygeng Professional 
software. X, Y and Z reconstruction images (left) and a representative image with a line indicating the zone of Z profile (right) are shown. 
Yellow arrowheads indicate Gal1 distribution in RA and in OIR endothelial cells. Abbreviations: ILM, inner limiting membrane; GCL, 
ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; NV, 
neovascularization; GC: ganglion cell.
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P17 and P26 OIR and did not colocalize with Gal1 (Figure 
3C, bottom panel), consistent with the ability of α2,6-
linked sialic acid to mask Gal1-specific glyco-epitopes 
[32].  These results indicate that OIR conditions alter 
the ‘glycosylation signature’ of the normal retina and 
suggest that areas with NV display a glycosylation pattern 
permissive for Gal1 binding as evidenced by increased 
amount of β1-6GlcNAc-branched complex N-glycans, 
abundant LacNAc structures and reduced α2,6 sialylation 
of cell surface glycoproteins respect to RA retinas.
Anti-VEGF treatment selectively controls 
neovascular but not other pathologic components 
in the OIR mouse model
A single intraocular injection of anti-VEGF 
(bevacizumab) administered at P12 in OIR mice improved 
vascular alterations present in P17 mouse retinas of 
vehicle-injected OIR eyes (controls) (Figure 4A). 
Quantitative analysis revealed a decrease of more than 
90% and 40% of retinal NV and VO areas, respectively 
Figure 3: Glycosylation profile of RA and OIR mouse retinas. Representative staining of LEL A., L-PHA B. and SNA C. in red 
(upper panel) and its combination with anti-Gal1 in green (bottom panel) in cryosections of P12, P17 and P26 RA and OIR retinas. Cell 
nuclei were counterstained with Hoechst 33258 (blue). Arrows indicate areas of colocalization in neovessels (yellow). All the experiments 
were performed in triplicate and are representative of three independent experiments. Abbreviations: ILM, inner limiting membrane; 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; NV, 
neovascularization. Scale bar: 25 µm.
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following anti-VEGF treatment (Figure 4B). However, we 
observed a considerable number of TUNEL-positive cells 
at P17 and P26 in retinas of OIR control and anti-VEGF-
treated mice (Figure 4C). Moreover, we found diminished 
expression of total caspase-3 in retinal extracts of OIR 
mice in response to anti-VEGF treatment at P17, an effect 
that was more pronounced at P26 (Figure 4D), indicating 
caspase cleavage toward its active form. However, 
despite attenuation of vascular phenotypes, alterations in 
GFAP and GS expression were still observed after anti-
VEGF treatment (Figure 4E and 4F). In line with these 
observations, decrease of scotopic electroretinogram 
retinal response observed in OIR mice (vehicle controls) 
could not be prevented by anti-VEGF treatment even 
at P26 (Figure 4G). Of note, no differences in TUNEL 
staining, GFAP expression and ERG signals were observed 
between OIR mice injected with vehicle (PBS) or non-
injected mice (data not shown). These findings suggest 
that anti-VEGF therapy does not improve non-vascular 
alterations associated with NV, including neuronal damage 
and glial activation and does not amend retinal functional 
impairment in OIR mice.
Modulation of the Gal1-glycan axis in OIR mouse 
retinas in response to anti-VEGF treatment
The fact that anti-VEGF treatment reduced the 
amount of neovascular tufts at P17 but did not improve 
the associated non-vascular alterations in OIR retinas, 
prompted us to investigate the impact of VEGF blockade 
on Gal1 expression and glycan profiles. Results indicated 
that administration of anti-VEGF at P12 significantly 
reduced VEGF protein expression in P17, respect to 
vehicle-injected OIR mouse samples to similar levels to 
those observed in RA retinas. However, targeting VEGF 
in OIR mouse retinas did not alter Gal1 expression 
(Figure 5A and 5B). Moreover, Gal1 mRNA levels were 
still elevated in retinas of anti-VEGF-treated OIR respect 
to RA mice (Figure 5C) and localization of this lectin in 
retinal tissue was not significantly altered in response 
to this treatment (Figure 5D upper panel). This result 
suggests that retinal Gal1 expression is independent of 
VEGF. 
To investigate possible alterations in the 
‘glycosylation signature’ of OIR mouse retinas following 
anti-VEGF treatment, we glycophenotyped this tissue 
using a panel of plant lectins as described in Figure 3. 
Double fluorescence assays showed colocalization of Gal1 
with LEL or L-PHA following VEGF blockade similar 
to that found in vehicle-injected OIR control retinas 
(Figure 5D second and third panels). However, because 
of the absence of NV in anti-VEGF treated mouse retinas, 
specific colocalization of Gal1 and L-PHA within the 
vascular compartment was not observed in anti-VEGF 
treated group (Figure 5D third panel). Furthermore, when 
we analyzed co-staining of Gal1 and SNA in anti-VEGF-
treated retinas, SNA reactivity was similar in both, treated 
or control retinas at P17 and, as expected, SNA did not 
colocalize with Gal1. Thus, targeting VEGF does not 
substantially alter the glycophenotype of retinal tissue in 
the OIR model. 
Notably, functional alterations observed in WT-OIR 
mice were partially prevented in Gal1-deficient (Lgals1-/-) 
OIR mice, mainly at P26. The scotopic responses resulted 
in significantly higher b-wave amplitude with a shorter 
latency in Lgals1-/- mice (Figure 5E), demonstrating 
improved retinal function in OIR mice lacking this 
endogenous lectin. 
Clinical relevance of Gal1 induction in 
neovascular retinopathies
To further extrapolate our results to clinical settings, 
we next examined Gal1 levels in the aqueous humor of 
diabetic patients with proliferative diabetic retinopathy 
or neovascular glaucoma or non-diabetic patients without 
neovascular retinopathies (controls). As shown in Table 1, 
we could find no significant differences between groups 
with regards to age, gender and duration of diabetes 
mellitus in patients with proliferative diabetic retinopathy 
and neovascular glaucoma. Interestingly, Gal1 levels 
increased considerably in proliferative diabetic retinopathy 
and neovascular glaucoma compared to control samples 
(Figure 6). Moreover, the highest Gal1 expression was 
observed in the aqueous humor of neovascular glaucoma 
respect to proliferative diabetic retinopathy patients. 
This could be explained by the extent of neovessels 
proliferation in neovascular glaucoma, an end-stage 
complication of proliferative diabetic retinopathy. Thus, 
similar to the experimental OIR model, Gal1 levels are 
also increased in the aqueous humor of patients with 
retinal neovascular disorders.
DISCUSSION
Pathological retinal angiogenesis is a leading cause 
of serious vision loss in potentially blinding eye diseases 
such as proliferative diabetic retinopathy and retinopathy 
of prematurity [1, 34-36]. Current therapeutic modalities, 
including “panretinal” laser photocoagulation to reduce 
retinal and optic nerve head NV, focal photocoagulation 
and, more recently the intraocular injections of anti-VEGF 
agents, has sparked a dramatic shift in the treatment of 
proliferative diabetic retinopathy and diabetic macular 
edema. However, in most patients the clinical efficacy 
of these treatments is limited and the complications of 
diabetes mellitus still represent one of the leading causes 
of vision loss worldwide. 
Previous studies stated that an ideal therapeutic 
treatment for ischemic retinopathies should combine 
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Figure 4: Impact of anti-VEGF treatment in the OIR mouse model. A. Representative images of whole mount retinas at P17 
OIR showing GSA-IB4 vascular staining in PBS (control) or anti-VEGF-injected eyes. Areas with VO and NV are indicated. Scale bar: 100 
µm. B. The VO (%) was quantified as the ratio of central avascular area to whole retinal area and the NV (%) was quantified as a percentage 
of whole retinal area. Data are presented as mean ± SEM. **p < 0.01, *** p < 0.001. C. Representative TUNEL-labeled cryosections of 
OIR mice injected or not with anti-VEGF at P17 and P26. Scale bar: 50 µm. D. and E. Representative Western blot of total caspase-3, GFAP 
and GS from neural retina extracts of RA and OIR mice injected or not with anti-VEGF mAb at P17 and P26. β-actin is shown as a loading 
control. F. Levels of GFAP and GS were quantified by densitometry and normalized to β-actin. Graph shows results of four independent 
experiments. G. Amplitudes and latencies of a- and b-waves from scotopic ERG were recorded at P17 and P26 in OIR mice injected or not 
with anti-VEGF mAb. Data show the average of responses in both eyes with five mice per condition. Data are presented as mean ± SEM 
or as median and interquartile range according to parametric or not parametric test used for analysis. ns, non-significant, *p < 0.05, **p < 
0.01, *** p < 0.001.
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the normalization of remaining vasculature and the 
attenuation or prevention of tissue neurodegeneration 
[34, 36]. It is well known that Müller glial cells and 
neurons are compromised in experimental neovascular 
retinopathies, such as in the OIR mouse model [37-39], 
and that gliosis may contribute to NV and neuronal cell 
Figure 5: Gal1 expression and function as well as the glycophenotype of mouse OIR retinas after anti-VEGF therapy. 
A. Representative Western blot of Gal1 and VEGF from P17 neural retinal extracts of RA and OIR mice injected or not with anti-VEGF 
mAb. β-actin is shown as a loading control. B. Levels of Gal1 and VEGF were quantified by densitometry and normalized to β-actin. Graph 
shows results of three independent experiments. C. Gal1 mRNA levels were quantified by qRT-PCR in neurosensory retinas of P17 OIR 
mice, injected or not with anti-VEGF mAb, and RA (control) conditions. Results were normalized to β-actin and expressed according to 
the 2-ΔΔCt method using as calibrator the mRNA level obtained from P17 RA mouse retinas. Data are presented as mean ± SEM or as median 
and interquartile range according to parametric or not parametric test used for analysis. ns, non-significant, *p < 0.05, **p < 0.01, *** p < 
0.001. D. Representative immunofluorescence analysis of Gal1 (green) or in combination with LEL (red, second panel), L-PHA (red, third 
panel) or SNA (red, bottom panel), in cryosections of P17 OIR mice injected or not with anti-VEGF. Abbreviations: ILM, inner limiting 
membrane; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear 
layer; NV, neovascularization. Scale bar: 25 µm. E. Amplitudes and latencies of a- and b-waves from scotopic ERG were recorded at P17 
and P26 in OIR and Lgals1-/- mice. Data show the average of responses in both eyes with three mice per condition. Data are presented as 
mean ± SEM or as median and interquartile range according to parametric or not parametric test used for analysis. ns, non-significant, *p 
< 0.05, **p < 0.01, *** p < 0.001.
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death [40]. Here, we observed an increase of retinal cell 
death in OIR mice consistent with other studies [41-43] 
and a persistent induction of GFAP which is expressed in 
activated Müller glial cells when retinas were injured [12, 
44, 45]. In this regard, it is known that persistent gliosis 
can impair the recycling of neurotransmitters such as 
glutamate, which accumulation in the retinal milieu causes 
neurotoxicity [46]. GS, a key neuroprotective enzyme that 
converts glutamate into glutamine [47], showed decreased 
expression in both P17 and P26 OIR retinas. Interestingly, 
and in line with these results, we observed an altered 
retinal function measured by ERG. The b-wave amplitude 
(mainly INL cell response [37]) was decreased at P17 
and P26 OIR and a- and b-wave latencies were increased 
at P26 respect to RA mice, which may be attributed to 
synaptic contacts loss and even neuronal death in the inner 
retina. Although many studies have previously reported 
similar alterations in P17 OIR retinas [9, 37, 43], here we 
detected their persistence until P26 OIR despite vascular 
normalization.
It was reported that Gal1 is involved in pathological 
NV and its therapeutic targeting attenuates aberrant 
angiogenesis in cancer and endometriosis [17, 18, 48-
51]; however its role in neovascular retinopathies is 
still uncertain. In the OIR mouse model, the peak of the 
proliferative phase (NV) is reached at P17 due to the 
up regulation of VEGF mostly in glial cells of the inner 
retina [32]. In addition to increased retinal VEGF at P17 
in the OIR mouse model, we demonstrated induction 
of Gal1 at protein and mRNA levels under hypoxic 
conditions. Moreover, Gal1 was localized mainly in 
retinal layers close to the vitreous humor in both OIR 
and RA conditions; however, it was enriched in areas 
with high NV in P17 OIR retinas. Immunofluorescence 
staining suggested its presence in astrocytes, as observed 
in brain tissue [52] as well as in Müller glial cells similar 
to expression in chicken retina [53]. In addition, at P17, 
Gal1 was found inside endothelial cells in neovascular 
tufts (OIR) but not in normal vessels (RA). Accordingly, 
we demonstrated here that Gal1 is significantly increased 
in the aqueous humor of diabetic patients with neovascular 
retinopathies. Interestingly, patients with neovascular 
glaucoma exhibited the highest Gal1 levels, an effect that 
could be associated to the aggressiveness of neovascular 
proliferation. Interestingly, targeting galectin-3 (Gal3) by 
33DFTG, a novel small molecule inhibitor, ameliorates 
pathological corneal angiogenesis as well as fibrosis [54]. 
Of note, this inhibitor also binds to Gal1, suggesting that 
it may control ocular and tumor angiogenesis by inhibiting 
the effects of both lectins. 
In previous studies we showed that interactions 
between Gal1 and specific target N-glycans link tumor 
hypoxia to NV in Kaposi’s sarcoma through mechanisms 
involving reactive oxygen species (ROS)-dependent 
activation of the transcription factor nuclear factor-κB 
(NF-κB) [17]. Interestingly, ROS have been linked to 
neovascular retinopathies and antioxidants have been 
proposed as possible therapeutics agents in proliferative 
Figure 6: Relevance of Gal1 in human proliferative retinopathies of diabetic patients. Representative graph of Gal1 levels 
in the aqueous humor of control and diabetes mellitus patients with proliferative diabetic retinopathy or neovascular glaucoma. Data are 
presented as median and interquartile range. ns, non-significant, *p < 0.05, *** p < 0.001.
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retinopathies [55-57]. Moreover, in OIR conditions and 
during NV, we observed a glycosylation pattern in retinal 
tissue permissive to Gal1 binding, as reflected by increased 
β1-6GlcNAc-branched N-glycans and poly-LacNAc 
structures together with reduced α2,6 sialylation compared 
to RA retinas. Accordingly, it has been reported that the 
N-glycan profile is altered during diabetic retinopathy 
[58], suggesting involvement of galectin-glycan lattices 
in these ophthalmologic disorders. 
The prominent Gal1 expression in OIR retinas 
was also maintained at P26 even when retinal vascular 
alterations were resolved. This observation suggests 
its involvement not only in retinal NV but also in 
other processes related to neovascular retinopathies 
physiopathology. In this regard, the role of Gal1 in 
neurodegeneration following brain injury has been largely 
appreciated. It has been reported that Gal1 is involved 
in the regulation of astrocyte reactivity [59] and that 
this lectin is important for modulating phagocytosis, 
inflammation, gliosis and axon growth after spinal cord 
injury [60, 61]. Moreover, astrocyte-derived Gal1 has 
been proposed to play a role in neuromodulation and 
microglia polarization in a model of multiple sclerosis 
[24] and in axonal degeneration in a model of amyotrophic 
lateral sclerosis [62]. Recently, it has been observed that 
Gal1 is upregulated 2-fold in zebrafish retina during 
experimental degeneration [63], suggesting that it could 
play an important role in the repair of the zebrafish retina 
by providing a permissible environment for regeneration. 
However, since neural retina displays substantial 
differences with other nervous system circuits, further 
studies are needed to dissect the role of Gal1 in retinal 
neurodegeneration in different organisms. 
Intravitreal injections of anti-VEGF agents are 
increasingly used for the treatment of a wide variety of 
retinal diseases. However, the clinical efficacy of VEGF-
targeted therapy is limited and many patients develop 
resistance to these drugs [64]. Our results demonstrate 
that anti-VEGF mAb injection at P12 OIR inhibited 
NV and reduced VO, as previously reported [65, 66], 
and normalized retinal VEGF levels at P17. However, 
other pathologic manifestations including gliosis, GS 
expression decrease and retinal cell death (non-vascular 
alterations) were preserved in comparison to vehicle-
injected OIR retinas. Likewise, altered electroretinogram 
in OIR mice revealed no significant improvement 
after intravitreal administration of anti-VEGF agents, 
indicating that this therapy did not contribute to functional 
preservation of the neural retina. Notably, deletion of 
Gal1 significantly improved neuronal function, during 
retinal ischemia mainly in P26 OIR. These results 
suggest that, in addition to NV, retinal neurodegeneration 
should also be considered an important pathogenic 
component of the disease that could be targeted with 
appropriate neuroprotective drugs. Our results revealed 
that Gal1 protein and mRNA increased progressively 
beyond P17 in OIR even after anti-VEGF treatment 
demonstrating a neovascular and neurodegenerative role 
of this lectin in NV-associated retinal dysfunction. In 
this regard, we recently demonstrated that Gal1 confers 
resistance to anti-VEGF treatment in different tumor 
types [30]. Interestingly, tumor-derived Gal1 increased 
considerably following VEGF blockade, suggesting that 
spatiotemporal regulation of individual galectins, their 
selective modulation by hypoxia and the repertoire of 
glycan structures displayed by tumor vessels, foster the 
development of a glycosylation-dependent compensatory 
program that preserves the angiogenic phenotype [30]. 
These results suggest the possibility of combining VEGF-
targeted and Gal1-targeted therapies, as has been proposed 
with other angioregulatory molecules for the treatment of 
neovascular retinopathies [48]. In conclusion, our study 
highlights the importance of non-vascular alterations 
in proliferative retinopathies and the need of seeking 
new therapeutic agents targeting both neovascular and 
neurodegenerative processes to treat this multifactorial 
disease. Our results underscore the role of Gal1 in the 
pathogenesis of neovascular retinopathies and suggest 
potential combination therapies based on simultaneous 
VEGF and Gal1 blockade in order to attenuate both 
vascular and non-vascular components. 
Table 1: Clinical features of retinopathy patients
Cataract (Control group) Proliferative Diabetic Retinophaty Neovascular Glaucoma 
Number of Samples 6 9 7
Agea 70 (60-82) ns 66 (55-74) ns 64 (56-78) ns
Gender (M/W) 4 (67%)/2 (33%) ns 4 (44%)/5 (56%) ns 5 (71%)/2 (29%) ns
Duration of DMb N/A 18 (5-43)b ns 15 (10-24)b ns
DM, Diabetes Mellitus; N/A, not applicable.
a Age is mean (extreme values) in years.
b Duration of DM is mean (extreme values) in years.




WT controls (C57BL/6J) and mice deficient in 
Gal1 (Lgals1-/-) on C57BL/6 background were handled 
according to guidelines of the ARVO Statement for the 
Use of Animals in Ophthalmic and Vision Research. 
Lgals1-/-mice were provided by Dr. F. Poirier (Jacques 
Monod Inst, Paris). Experimental procedures were 
designed and approved by the Institutional Animal Care 
and Use Committee (CICUAL) of the Faculty of Chemical 
Sciences, National University of Córdoba (Res. HCD 
451/07). All efforts were made to reduce the number of 
animals used.
Oxygen-induced retinopathy (OIR) mouse model
In a typical model of OIR [31], litters of mice pups 
with their nursing mothers were exposed in an infant 
incubator to high oxygen concentration (75% ± 2%) for 
5 days (hyperoxic period, P7-P12). Oxygen was checked 
twice daily with an oxygen analyzer (Teledyne Analytical 
Instruments, CA, USA). Next, mice were housed in RA for 
an additional time period of 5 or 14 days (relative hypoxic 
period, P12-P17 or P12-P26). Age-matched control 
C57BL/6 mice were exposed continuously to RA. Animals 
were maintained in clear plastic cages with standard light 
cycles (12 h light/12 h dark). 
At P12, some OIR mice were intravitreally 
injected with 1.0 µL solution containing 1.25 µg anti-
VEGF (Bevacizumab; Genentech, San Francisco, CA) 
as previously reported [66], being representative of the 
equivalent dose of 1.25 mg anti-VEGF given intravitreally 
to patients. For 1.25 µg injection, the original commercial 
solution (25 µg/µL) was diluted 1/20 with phosphate 
buffered saline (PBS) to obtain 1.25 µg/µL concentration 
and then 1.0 µL was immediately injected into the 
vitreous. Vehicle (PBS)/-injected mice were used as 
controls. Briefly, pups were locally anesthetized with 
one with one drop of proparacaine hydrochloride 0.5% 
(Anestalcon, Alcon), exophthalmia was induced with one 
drop of tropicamide 1% (Midril, Alcon, Buenos Aires, 
Argentina) and eyes were punctured at the upper nasal 
limbus as described previously [12]. 
All mice were sacrificed at three typical times 
in the OIR mouse model: P12 (maximum VO), P17 
(maximum NV) and P26 (vascular alteration resolution) 
[31]. Eyes or retinas of sacrificed mice were collected and 
processed for Western blot, real-time PCR (qRT-PCR), 
immunohistochemistry, immunofluorescence or flat-
mount assays. At least six mice per group were used for 
each condition in the survival times examined. Data were 
collected from both males and females and the results 
were combined as there were no apparent sex differences.
Electroretinography (ERG)
Electroretinographic activity was assessed at P17 
and P26 RA, OIR with or without anti-VEGF treatment in 
WT or Lgals1-/-mice, as previously described [37]. Briefly, 
after overnight (ON) dark adaptation and under dim red 
illumination, mice were anesthetized via intra-peritoneal 
injections with a solution containing appropriate doses 
of ketamine / xilacine, the pupils were dilated with 1% 
tropicamide and the cornea was lubricated with gel drops 
of 0.4% polyethylene glycol 400 and 0.3% propylene 
glycol (Systane, Alcon, Buenos Aires, Argentina) to 
prevent damage. Mice were exposed to stimuli at a 
distance of 20 cm. A reference electrode was inserted 
on the back between the ears, a grounding electrode was 
attached to the tail, and a gold electrode was placed in 
contact with the central cornea. Electroretinograms were 
simultaneously recorded from both eyes and ten responses 
to flashes of unattenuated white light (5 cd.s/m2, 0.2 Hz) 
from a photic stimulator (light-emitting diodes) set at 
maximum brightness were amplified, filtered (1.5-Hz 
low-pass filter, 1000 high-pass filter, notch activated) and 
averaged (Akonic BIO-PC, Argentina).
The a-wave was measured as the difference in 
amplitude between the recording at onset and trough of 
the negative deflection, and the b-wave amplitude was 
measured from the trough of the a-wave to the peak of 
the b-wave. The latencies of the a- and b-waves were 
measured from the time of flash presentation to the trough 
of the a-wave or the peak of the b-wave, respectively. 
Responses were averaged across the two eyes for each 
mouse.
Labeling of flat-mount retinas
Mice were euthanized at P17 and eyes were 
enucleated and fixed with freshly prepared 4% 
paraformaldehyde (PFA) for 1-2 h at room temperature 
(RT). Corneas were removed with scissors along the 
limbus and the whole retinas were dissected. Then, they 
were blocked and permeabilized in Tris-buffered saline 
(TBS) containing 5% Bovine Serum Albumin (BSA) and 
0.1% Triton-X-100 during 6 h at 4 °C. After that, retinas 
were incubated ON with 0.02 µg/µL of Isolectin IB4 Alexa 
fluor-488 conjugate (GSA-IB4) from Molecular Probes, 
Inc. (Eugene, OR, USA). Retinas were then washed with 
TBS containing 0.1% Triton-X-100, stored in PBS at 4 
°C and examined by confocal laser-scanning microscopy 
(Olympus FluoView FV1200; Olympus Corp., New York, 
NY, USA).
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Retinal cryosection, protein extract and RNA 
sample preparation
For cryosection, eyes were enucleated, fixed during 
1-2 h with 4% PFA at RT, and incubated ON in 10%, 
20% and 30% of sucrose in PBS at 4 °C. Then, they 
were embedded in optimum cutting temperature (OCT) 
(Tissue-TEK, Sakura) compound, and 10-μm-thick radial 
sections were obtained by using a cryostat, according to 
general methods as described [39]. Retinal cryosections 
were then stored at -20 °C under dry conditions until 
immunohistochemical analysis.
Neural retinas were dissected from RPE/choroid 
layers for Western blot and qRT-PCR analysis. Protein 
extracts were obtained from retinas after homogenization 
with a lysis buffer containing 20 mM Tris-HCl pH 7.5, 
137 mM NaCl, 2 mM EDTA pH 8, 1% Nonidet P40, 
1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM 
sodium ortovanadate and protease inhibitor cocktail 
(Sigma Aldrich, St. Louis, MO) [39], and were sonicated 
during 20 sec at 40 % amplitude. In addition, some neural 
retinas were disrupted in 500 µL Trizol (Invitrogen) and 
were stored at -80 ˚C until RNA extraction. All the assays 
were performed in triplicate and results are representative 
of at least three independent experiments (animals in each 
group).
Immunofluorescence and lectin labeling in 
cryosections
For detection of Gal1 in combination with GFAP, 
GS and CD31 (PECAM-1) or for LEL, SNA and L-PHA 
lectin histochemistry, mice cryosections were washed in 
TBS, blocked with 2% of BSA in TBS containing 0.1% 
Triton-X-100, for 1 h and then incubated ON at 4 °C with 
the biotinylated lectins (1/200; Vector laboratories) and 
the following primary antibodies, respectively: mouse 
monoclonal (1/50) or rabbit polyclonal (1/50) anti-Gal1 
obtained as described [30], rabbit polyclonal anti-GFAP 
(1/100; Dako, Carpinteria, CA), rabbit polyclonal anti-
GS (1/100; Abcam Inc., Cambridge, MA) and mouse 
monoclonal anti-CD31 (1/50; Abcam Inc., Cambridge, 
MA). Then, sections were washed with TBS 0.1% 
Triton-X-100 and incubated with Alexa Fluor 555 
streptavidin (Thermo Fisher Scientific Inc) or secondary 
antibodies including goat against rabbit or mouse IgG 
conjugated with Alexa Fluor 488 and 594 (Molecular 
Probes, Eugene, OR, USA) respectively, during 1 h at 
RT. The sections were also counterstained with Hoechst 
33258 (1:3000 dilution; Molecular Probes) for 7 min. 
After a thorough rinse, the sections were mounted 
with Fluor Save (Calbiochem, La Jolla, CA) and cover 
slipped. The labeling was visualized using a confocal 
laser-scanning microscope (Olympus Fluvial FV300 
or FV1200; Olympus Corp., New York, NY, USA). 
Finally, images were processed with microscope software 
Viewer Fluoview 4.0 software (Olympus) and Image J 2 
software (National Institutes of Health, Bethesda, MD, 
USA). Negative controls without incubation with primary 
antibody or biotinylated lectin were carried out to avoid 
unspecific staining (data not shown).
Western blot
Protein concentration of retinal extracts were 
determined by a BCA kit (Pierce, Buenos Aires, Argentina) 
and 10 - 20 µg of proteins were electrophoresed in 
15% SDS-PAGE. After electrophoresis, proteins were 
transferred to nitrocellulose membranes (Amersham 
Hybond ECL; GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden). To prevent nonspecific binding, membranes 
were blocked with 5% milk in TBS containing 0.1% 
Tween-20 (TBST) during at least 1 h at RT. Then, blots 
were incubated with primary antibodies diluted in TBST 
or 5% BSA in TBST for 1 h at RT or ON at 4 ºC, according 
to the antibody. The following antibodies were used: rabbit 
polyclonal (1.5µg/ml; anti-Gal1 generated as described 
[30]), mouse monoclonal anti-VEGF (1/500; R&D 
system), rabbit polyclonal anti-GFAP (1/1000; Dako, 
Carpinteria, CA), mouse monoclonal anti-GS (1/500; 
Millipore Corporation MA, USA), rabbit polyclonal anti-
caspase 3 (Sigma-Aldrich) and mouse monoclonal anti-β-
actin (1/2000; Sigma-Aldrich). Blots were incubated with 
IRDye 800 CW donkey anti-rabbit Ig or IRDye 800 CW 
donkey anti-mouse IgG antibodies (1/15000 in TBS with 
5% BSA) for 1 h, protected from light. After washing with 
TBST, membranes were visualized and quantified using 
the Odyssey Infrared Imaging System (LI-COR, Inc., 
Lincoln, NE, USA).
qRT-PCR
Total RNA was extracted from neural retinas using 
Trizol (Invitrogen), according to the manufacturer’s 
instructions and was processed as previously reported 
[67]. Briefly, 1 µg of total RNA was reverse-transcribed in 
a total volume of 20 µL using random primers (Invitrogen, 
Buenos Aires, Argentina) and 50 U of M-MLV reverse 
transcriptase (Promega Corp.). For qPCR, cDNA was 
mixed with 1x SYBR Green PCR Master Mix (Applied 
Biosystems) and the forward and reverse primers (Gal1 
forward: TCAGCCTGGTCAAAGGTGAT/ Gal1 
reverse: TGAACCTGGGAAAAGACAGC). qPCR 
were carried out on an Applied Biosystems 7500 Real-
Time PCR System with Sequence Detection Software 
v1.4. The cycling conditions included a hot start at 95 °C 
for 10 min, followed by 40 cycles at 95 °C for 15 sec 
and 60 °C for 1 min. Specificity was verified by melting 
curve analysis. Results were normalized to β-actin 
(Forward: GGCTGTATTCCCCTCCATCG/ Reverse: 
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CCAGTTGGTAACAATGCCATGT). Relative gene 
expression was calculated according to the 2-ΔΔCt method. 
Each sample was analyzed in triplicate. No amplification 
was observed in PCRs using as template water or RNA 
samples incubated without reverse transcriptase during the 
cDNA synthesis (data not shown).
TUNEL assay
Cell death was examined by terminal 
deoxynucleotidyltransferase biotin dUTP nick end 
labeling (TUNEL) assay (Roche, Mannheim, Germany) 
following the manufacturer’s instructions. Slides were 
counterstained with methyl green to visualize retinal layers 
and then mounted with DPX Mounting Media (Sigma-
Aldrich, St. Luis, MO). Negative controls without enzyme 
were processed in order to avoid false positive results 
(data not shown). For each section, TUNEL-positive 
nuclei staining brown were counted from three randomly 
selected fields on either side of the optic nerve and the 
average values from three separates sections/eye crossing 
the optic nerve were combined to produce a mean value. 
The interval between each section was 15 mm apart. The 
field size of each picture was approximately 0.05 mm2. 
Images were obtained under a light microscope (Nikon 
Eclipse TE2000-E, USA). 
Patient samples
The protocol for this study was approved by 
the Oulton Romagosa Ethics Committee and Córdoba 
Ministry of Health (Argentina) and the study was 
conducted according to standards of Helsinki Declaration. 
Written informed consent was obtained from all 
participants before their enrollment. Patients older than 
21 years old with type-2 diabetes mellitus were recruited 
between January 2016 and July 2016 from Centro Privado 
de Ojos Romagosa-Fundación Ver (Cordoba, Argentina). 
Type 2 diabetes mellitus was diagnosed according to 
the American Diabetes Association (2005) criteria [68]. 
Patients were defined as a self-reported previous history of 
physician-diagnosed type 2 diabetes mellitus treated with 
insulin or oral hypoglycemic agents and those having a 
diagnosis of diabetes of at least 5 years were selected. The 
duration of the disease was defined as the interval between 
the first diagnosis of diabetes and the time of enrollment 
in the present study. A questionnaire was conducted 
to obtain basic information (age & sex), and additional 
data (including the use of insulin and oral hypoglycemic 
therapy and any history of other systemic diseases). A 
complete ophthalmological examination included an 
external examination of the eye and anexa (including 
conjunctiva, sclera and lid position or abnormalities), pupil 
responsiveness (including but not limited to abnormal 
pupil shape, unequal pupils, abnormal reaction to light 
or afferent pupillary defect), slit-lamp biomicroscopic 
examination (cornea, anterior chamber, iris, and lens). 
Intraocular pressure measurements performed using a 
Goldmann applanation tonometer performed prior to pupil 
dilation. The examination also included a dilated indirect 
ophthalmoscopic examination (including evaluation of 
the posterior segment and vitreous, optic nerve, retinal 
vasculature, peripheral retina, and macula) conducted 
by one of the 2 retinal specialist and dilated fundus 
photography was done after the complete examination. 
Seven fields of 30° color fundus photographs with 
stereoscopic images of the optic disc and macula were 
taken through the dilated pupils of each patient, using a 
digital fundus camera (Zeiss Visucam Pro; Oberkochen, 
Germany). Two retinal specialist ophthalmologists 
determined the presence and classification of proliferative 
diabetic retinopathy in a masked manner. All proliferative 
diabetic retinopathy and neovascular glaucoma patients 
had, during the last 2 months prior to surgery, different 
degrees of active neovascularization (disk, arcade or 
neovascular glaucoma) with or without tractional retinal 
detachment. Anterior chamber taps were performed under 
topical anesthesia by microscopic observation of the eye 
with the patient lying down under a surgical microscope. 
All this procedure was taken before an intraocular 
injection of antiangiogenic drug has been applied. By 
contrast, control group samples were taken before cataract 
surgery. A drop of 5% povidone iodine was applied to 
the eye and a limbal paracentesis was performed with a 
sterile tuberculin syringe with a 30-gauge needle. It was 
inserted into the anterior chamber, and 0.2 ml of aqueous 
was removed and stored frozen at -80°C until assayed. 
Nine samples were collected from diabetic patients with 
proliferative diabetic retinopathy, seven samples from the 
patients with neovascular glaucoma, all with end-stage of 
proliferative diabetic retinopathy, and six samples from 
non-diabetic patients undergoing cataract were used as a 
control group as was previously described [69]. Patients 
with a vitreous hemorrhage were not included in this 
study. 
ELISA
Gal1 was determined using an in-house ELISA as 
described [30]. Aqueous humor was previously diluted 
1:5. Optical densities were determined at 450-550 nm 
in a Multiskan MS microplate reader (Thermo Electron 
Corporation).
Statistical analysis
Statistical analysis was performed using the 
GraphPad Prism 5.0 software. A p-value < 0.05 was 
considered statistically significant. Parametric or 
nonparametric tests were used according to variance 
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homogeneity evaluated by F or Barlett´s tests. Two-tailed 
unpaired t or Mann Whitney tests were used in analysis 
of two groups. One-way analysis of variance (ANOVA) 
followed by Dunnett´s multiple comparison post-test or 
Kruskal-Wallis followed by Dunn´s multiple comparison 
post-test were used to determine statistical significance 
among more than two different groups. Two-way ANOVA 
followed by Bonferroni post-test was used in comparisons 
between groups when two variables were affecting the 
dependent variable. Mean ± standard error (SEM) are 
shown in graphs analyzed with parametric tests and 
median with interquartile range are shown when data 
were analyzed with nonparametric tests as indicated in the 
figures.
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